Drugmakers GSK, Sanofi begin new COVID-19 vaccine trial after setback last year

Britain’s GlaxoSmithKline and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to reach the final testing stage in the second quarter.

If the results are conclusive, the two drugmakers hope to see the vaccine approved by the fourth quarter after having initially targeted the first half of this year.

For more coronavirus news, visit our dedicated page.

The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.

The new trial will aim at evaluating the safety, tolerability and immune response of the vaccine in 720 healthy adults across the US, Honduras and Panama, the companies said.

For all the latest headlines follow our Google News channel online or via the app.

Sanofi and GSK’s candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

The study will test two injections given 21 days apart.

Read more:

Coronavirus: GSK, Vir to test antibody for COVID-19 treatment

Sanofi, GSK to supply 200 mln vaccine doses to WHO-backed COVAX alliance

Coronavirus: US to provide Sanofi/GSK $2.1 bln fund to develop COVID-19 vaccine